Gabrielle Lyon: This GLP-1 Side Effect in Women Goes Completely Unreported
Peer-Reviewed Research
Key Takeaways
- Monitor sexual side effects if taking GLP-1 receptor agonists (e.g., Ozempic, Wegovy) – women’s reports are systematically understudied.
- Check FDA adverse event reports cautiously – only ~10% of side effects are captured, and sexual dysfunction is particularly underreported.
- Demand gender-specific safety data – current evidence for women’s safety with GLP-1 drugs is lacking, not just weak.
Notable Quotes
“The evidence for safety in women is not weak. It’s non-existent.”
Bottom Line
Women taking GLP-1 drugs should track and report sexual side effects (often missed in trials) and advocate for better gender-specific safety research.
Explore More
- Gabrielle Lyon’s Full Protocol — supplements, dosages, and daily routine
- Compare All Protocols — side-by-side protocols
Watch the Full Video
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.
Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.
No spam. Unsubscribe anytime. Powered by Beehiiv.
Related Research
From Our Research Network
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Part of the Evidence-Based Research Network